Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | CA12 | O43570 | 4/20 | 0.52 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | CA7 | P43166 | 4/20 | 0.52 |
| ▸ | CA9 | Q16790 | 4/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | CA4 | P22748 | 3/20 | 0.52 |
| ▸ | CA6 | P23280 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | CA3 | P07451 | 2/20 | 0.52 |
| ▸ | CA5A | P35218 | 2/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL988442 | 0.87 | TPMT (0.54) | KDM4EMAPTCA12CA1CA2 | |
| SCHEMBL1919748 | 0.84 | CA12 (0.64) | KDM4EMAPTCA12CA1CA2 | |
| SCHEMBL11305809 | 0.83 | PRKCI (0.47) | KDM4EMAPTCA2TDP1ALDH1A1 | |
| Water SCHEMBL4387068 | 0.82 | CA12 (0.61) | KDM4EMAPTCA12CA1CA2 | |
| Water SCHEMBL4387073 | 0.82 | CA12 (0.61) | KDM4EMAPTCA12CA1CA2 | |
| SCHEMBL3252847 | 0.81 | KDM4E (0.48) | KDM4EMAPTCA12CA1CA2 | |
| SCHEMBL2890085 | 0.79 | KDM4E (0.68) | KDM4EMAPTTDP1ALDH1A1HPGD | |
| SCHEMBL3684356 | 0.78 | CA12 (0.56) | KDM4EMAPTCA12CA1CA2 | |
| SCHEMBL4269298 | 0.78 | CA12 (0.70) | KDM4EMAPTCA12CA1CA2 | |
| SCHEMBL13199302 | 0.78 | CA12 (0.56) | KDM4EMAPTCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160175-A1 | 18,21-Didesoxymacbecin Derivatives for the Treatment of Cancer | MARTIN CHRISTINE | 2011-06-30 | — | — | US | disclosed |
| WO-2008056189-A1 | 18, 21-DIDESOXYMACBECIN DERIVATIVES FOR THE TREATMENT OF CANCER | BIOTICA TECHNOLOGY LIMITED (GB) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160175-A1 | 18,21-Didesoxymacbecin Derivatives for the Treatment of Cancer | BCL3, CD22, MEN1 | KDM4E 2473/4885MAPT 1295/4885CA12 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.